Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
2(40.0%)
Phase 2
1(20.0%)
N/A
1(20.0%)
Phase 4
1(20.0%)
5Total
Phase 3(2)
Phase 2(1)
N/A(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT01644682Phase 3Completed

Replacement of Insecticides to Control Visceral Leishmaniasis (VL)

Role: collaborator

NCT01566552Phase 4Unknown

Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis

Role: collaborator

NCT00371995Phase 2Completed

Short Course of Miltefosine and Liposomal Amphotericin B for Kala-azar

Role: collaborator

NCT00523965Phase 3Completed

Combination Therapy in Indian Visceral Leishmaniasis

Role: collaborator

NCT00318721Not ApplicableCompleted

Efficacy, Acceptability and Cost-effectiveness of Long Lasting Insecticide Nets (LLIN) in the Prevention of Kala Azar

Role: collaborator

All 5 trials loaded